style="font-size:15px;"> 193 193 Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008; 48(6):662–70.194 194 Yu J, Petrie ID, Levy RH, Ragueneau‐Majlessi I. Mechanisms and clinical significance of pharmacokinetic‐based drug‐drug interactions with drugs approved by the U.S. Food and Drug Administration in 2017. Drug Metab Dispos 2019; 47(2):135–44.
195 195 Aslanian R, Piwinski JJ, Zhu X, Priestley T, Sorota S, Du XY, et al. Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett 2009; 19 (17):5043–7.
196 196 Kamiya K, Niwa R, Morishima M, Honjo H, Sanguinetti MC. Molecular determinants of hERG channel block by terfenadine and cisapride. J Pharmacol Sci 2008; 108(3):301–7.
197 197 Roy M, Dumaine R, Brown AM. HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94(4):817–23.
198 198 Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996; 385 (1–2):77–80.
199 199 Raeissi SD, Hidalgo IJ, Segura‐Aguilar J, Artursson P. Interplay between CYP3A‐mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco‐2 (TC7) cell monolayers. Pharm Res 1999; 16(5):625–32.
200 200 Jurima‐Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver. in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22(6):849–57.
201 201 Herings RM, Stricker BH, Leufkens HG, Bakker A, Sturmans F, Urquhart J. Public health problems and the rapid estimation of the size of the population at risk. Torsades de pointes and the use of terfenadine and astemizole in The Netherlands. Pharm World Sci 1993; 15(5):212–8.
202 202 Pohjola‐Sintonen S, Viitasalo M, Toivonen L, Neuvonen P. Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia. Eur J Clin Pharmacol 1993; 45(2):191–3.
203 203 Paris DG, Parente TF, Bruschetta HR, Guzman E, Niarchos AP. Torsades de pointes induced by erythromycin and terfenadine. Am J Emerg Med 1994; 12(6):636–8.
204 204 Pohjola‐Sintonen S. Treatment with terfenadine and ketoconazole or itraconazole can cause torsades de pointes ventricular tachycardia. Duodecim 1993; 109(2):164–6.
205 205 Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59(4):383–8.
206 206 Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, et al. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol 1997; 52(4):311–5.
207 207 Honig PK, Wortham DC, Lazarev A, Cantilena LR. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol 1996; 36(4):345–51.
208 208 Rau SE, Bend JR, Arnold MO, Tran LT, Spence JD, Bailey DG. Grapefruit juice‐terfenadine single‐dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997; 61(4):401–9.
209 209 Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000; 95(1):272–6.
210 210 Gitlin N, Julie NL, Spurr CL, Lim KN, Juarbe HM. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998; 129(1):36–8.
211 211 Herrine SK, Choudhary C. Severe hepatotoxicity associated with troglitazone. Ann Intern Med 1999; 130(2):163–4.
212 212 Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4(6):489–99.
213 213 Meier Y, Cavallaro M, Roos M, Pauli‐Magnus C, Folkers G, Meier PJ, et al. Incidence of drug‐induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005; 61(2):135–43.
214 214 Bjornsson ES, Bergmann OM, Bjornsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug‐induced liver injury in the general population of Iceland. Gastroenterology. 2013; 144(7):1419–25, 25 e1‐3; quiz e19‐20.
215 215 Faich GA, Moseley RH. Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol Drug Saf 2001; 10(6):537–47.
216 216 Dixit VA, Bharatam PV. Toxic metabolite formation from Troglitazone (TGZ): new insights from a DFT study. Chem Res Toxicol 2011; 24(7):1113–22.
217 217 Prabhu S, Fackett A, Lloyd S, McClellan HA, Terrell CM, Silber PM, et al. Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem Biol Interact 2002; 142 (1–2):83–97.
218 218 Honma W, Shimada M, Sasano H, Ozawa S, Miyata M, Nagata K, et al. Phenol sulfotransferase, ST1A3, as the main enzyme catalyzing sulfation of troglitazone in human liver. Drug Metab Dispos 2002; 30(8):944–9.
219 219 Kostrubsky VE, Sinclair JF, Ramachandran V, Venkataramanan R, Wen YH, Kindt E, et al. The role of conjugation in hepatotoxicity of troglitazone in human and porcine hepatocyte cultures. Drug Metab Dispos 2000; 28 (10):1192–7.
220 220 Masubuchi Y. Metabolic and non‐metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab Pharmacokinet 2006; 21(5):347–56.
221 221 Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 2003; 16(6):679–87.
222 222 Tafazoli S, Spehar DD, O'Brien PJ. Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab Rev 2005; 37(2):311–25.
223 223 Galati G, Tafazoli S, Sabzevari O, Chan TS, O'Brien PJ. Idiosyncratic NSAID drug induced oxidative stress. Chem Biol Interact 2002; 142 (1–2):25–41.
224 224 Shibuya A, Watanabe M, Fujita Y, Saigenji K, Kuwao S, Takahashi H, et al. An autopsy case of troglitazone‐induced fulminant hepatitis. Diabetes Care 1998; 21 (12):2140–3.
225 225 Uetrecht J. Drug metabolism by leukocytes and its role in drug‐induced lupus and other idiosyncratic drug reactions. Crit Rev Toxicol 1990; 20(4):213–35.
226 226 Funk C, Pantze M, Jehle L, Ponelle C, Scheuermann G, Lazendic M, et al. Troglitazone‐induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (BSEP) by troglitazone and troglitazone sulfate. Toxicology 2001; 167(1):83–98.
227 227 Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone‐induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (BSEP) in the rat. Mol Pharmacol 2001; 59(3):627–35.
228 228 Okada R, Maeda K, Nishiyama T, Aoyama S, Tozuka Z, Hiratsuka A, et al. Involvement of different human glutathione transferase isoforms in the glutathione conjugation of reactive metabolites of troglitazone. Drug Metab Dispos 2011; 39 (12):2290–7.
